Eye

Diabetic Retinopathy

search

Diabetic Retinopathy, Diabetic Macular Edema

  • See Also
  1. Diabetes Complications
  • Epidemiology
  1. Occurs in 20% of patients with Diabetes Mellitus
  2. Occurs equally in Type I and Type II Diabetes Mellitus
  • Risk Factors
  1. Longer duration of Diabetes Mellitus (>72 months)
  2. Poor Blood Glucose control (Hgb A1C > 8.0)
  3. Increased Microalbuminuria levels (>9.5)
  4. Saum (2002) Br J Gen Pract 52:214-6 [PubMed]
  • Types
  1. Nonproliferative Retinopathy
    1. Retinal veins dilated
    2. Cotton Wool exudates or spots
    3. Hard exudates
    4. Macular edema
    5. Intraretinal Hemorrhages
    6. Microaneurysms
  2. Proliferative Retinopathy
    1. Neovascularization
    2. Preretinal Hemorrhages
    3. Vitreous Hemorrhages
    4. Vascular fibrosis
  • Symptoms
  1. Vision Loss, fluctuating Visual Acuity or Visual Field Defects
  2. Floater or flashes of light (photopsia)
  1. Children with Diabetes
    1. Initial Exam: Age 10 years (or after 3-5 years of Diabetes Mellitus)
    2. Subsequent Exams: Annually
  2. Adults with Type 2 Diabetes
    1. Initial Exam: At diagnosis
    2. Subsequent Exams: Annually
  1. Mild to moderate nonproliferative Diabetic Retinopathy
    1. No Macular edema
      1. Exams every 6-12 months
    2. Macular edema present
      1. Consider laser photocoagulation
      2. Intravitreal injection of Vascular Endothelial Growth Factors (e.g. Bevacizumab, aflibercept, ranibizumab)
        1. Wells (2015) N Engl J Med 372(13): 1193-203 +PMID:25692915 [PubMed]
      3. Intravitreal Corticosteroid Injection or implant (Cataract risk)
        1. Grover (2008) Cochrane Database Syst Rev (1):CD005656 +PMID:18254088 [PubMed]
  2. Severe nonproliferative Diabetic Retinopathy
    1. Eye Examinations every 2-4 months
    2. Consider laser photocoagulation
    3. See Macular edema management as above
  3. Proliferative Diabetic Retinopathy
    1. Consider laser photocoagulation
  4. Vitreous Hemorrhage (or refractory course)
    1. Intravitreal injection of Vascular Endothelial Growth Factors (e.g. Bevacizumab, aflibercept, ranibizumab)
      1. Osaadon (2014) Eye 28(5): 510-20 [PubMed]
  • Prevention
  • Slowing Diabetic Retinopathy progression
  1. Fenofibrate
    1. Wong (2012) Am J Ophthalmol 154(1): 6-12 [PubMed]
  2. Tighter glycemic control reduces progression risk
    1. However, diabetes goals have loosened to prevent Hypoglycemia (A1C 8.5% in older adults)
    2. Stratton (2001) Diabetologia 44(2): 156-63 [PubMed]
  • References
  1. Pelletier (2016) Am Fam Physician 94(3):219-26 [PubMed]